Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
|3 references available|
|Quantity||0.1 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
Reacts with a 170-180 kDa transmembrane glycoprotein (P-glycoprotein), a product of the multidrug resistance-1 (MDR1) gene. This glycoprotein is expressed on MDR positive cells and has been reported to be expressed on many normal tissues, such as adrenal glands and endothelium, in the brain and skin. P-glycoprotein is known to impart drug resistance to cells by pumping many anti-cancer drugs out of the cytoplasm. 17F9 antibody binds to the surface of the viable, unfixed MDR+ cell line, PMG-Y (please inquire), and is able to partially block the binding of UIC2 antibody (another MDR-specific monoclonal antibody). Immunoprecipitation application is reported, but not routinely tested in house.
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
|Application Notes||Positive control cells are available through special order|
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at 4° C.|
|Restrictions||For Research Use only|
|Profile of P-glycoprotein (MDR) expressed on PMG-Y cell line analyzed on a FACScan (BDIS, San Jose, CA)|
Bénard, Bourhis, Riou: "Clinical significance of multiple drug resistance in human cancers." in: Anticancer research, Vol. 10, Issue 5A, pp. 1297-302, 1990 (PubMed).
Goldstein, Galski, Fojo et al.: "Expression of a multidrug resistance gene in human cancers." in: Journal of the National Cancer Institute, Vol. 81, Issue 2, pp. 116-24, 1989 (PubMed).
Shi, Wrin, Reeder et al.: "High-affinity monoclonal antibodies against P-glycoprotein." in: Clinical immunology and immunopathology, Vol. 76, Issue 1 Pt 1, pp. 44-51, 1995 (PubMed).